)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Clearmind Medicine
Clearmind Medicine (CMND) investor relations material
Clearmind Medicine Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Sep, 2026
Executive summary
Engaged in Phase I/IIa clinical trials for non-hallucinogenic, psychedelic-derived neuroplastogens targeting neuropsychiatric, metabolic, and addiction disorders, with a primary focus on Alcohol Use Disorder (AUD).
Advanced clinical trial for CMND-100, with positive safety reviews and progression to higher dose cohorts and additional study parts.
Acquired a 51% stake in Charging Robotics, expanding into intelligent EV wireless charging solutions.
Financial highlights
Cash and cash equivalents as of July 31, 2026: $12.0 million, up from $3.9 million at October 31, 2025.
Net loss for Q3 2026: $0.9 million, improved from $1.3 million in Q3 2025; nine-month net loss: $6.8 million, up from $3.2 million year-over-year.
Operating expenses for Q3 2026: $2.2 million; nine months: $7.4 million.
Finance income for Q3 2026: $1.3 million, driven by changes in warrant liabilities and short-term investments.
Outlook and guidance
Cash position expected to provide liquidity for at least twelve months, but future capital requirements may exceed current resources depending on clinical trial progress.
Continued dependence on external financing for ongoing operations and program advancement.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Clearmind Medicine
- Q1 2026 saw a $3.85M net loss, higher expenses, and a strengthened cash position.CMND
Q1 2026 - Clinical trials advanced, net loss widened, cash position strengthened via new financings.CMNDQ2 2026
- Psychedelic drug developer seeks $10M convertible note to fund trials, enabling resale of up to 22.6M shares.CMNDRegistration filing
- Novel psychedelic AUD therapy in clinical trials, funded by convertible notes, faces dilution and geopolitical risks.CMNDRegistration Filing
- Net loss narrowed, but ongoing losses, no revenue, and funding needs raise going concern risk.CMNDQ4 2025
- Developing psychedelic therapies for AUD and obesity, but faces ongoing losses and high risk.CMNDRegistration Filing
- Registering up to 17M shares for resale, funding R&D of non-hallucinogenic psychedelic therapies.CMNDRegistration Filing
- Psychedelic drug developer registers resale of 5.78M shares amid clinical trials and compliance risks.CMNDRegistration Filing
- Clinical trials advanced, net loss narrowed, but future financing remains critical.CMNDQ3 2025
Next Clearmind Medicine earnings date
Q4 202620 Jan, 2027
Clearmind Medicine
Next Clearmind Medicine earnings date
Q4 202620 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Clearmind Medicine Inc is a Canada-based biotechnology company focused on the research and development of psychedelic-derived therapeutics for the treatment of mental health conditions. The company is developing proprietary compounds aimed at addressing issues such as alcohol use disorder, depression, and anxiety. Clearmind’s approach combines psychedelic science with pharmaceutical development to create regulated treatment options. The company is headquartered in Vancouver, British Columbia, and its shares are listed on the CSE.